Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Sana Biotechnology, Inc. on June 5, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Seattle, Washington.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders approved two key proposals at the Annual Meeting:
- Proposal 1 (Director Elections): All four Class I director nominees were elected to three-year terms expiring in 2028. Voting results were as follows:
- Steven D. Harr, M.D.: 147,857,094 For; 11,540,847 Withheld.
- Robert L. Rosiello: 158,192,667 For; 1,205,274 Withheld.
- Michelle Seitz, CFA: 147,879,439 For; 11,518,502 Withheld.
- Patrick Y. Yang, Ph.D.: 143,651,313 For; 15,746,628 Withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- For: 180,193,873
- Against: 55,838
- Abstain: 69,644
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the final vote tallies.
Investor Verification Checklist
- Verify the total number of shares entitled to vote at the Annual Meeting to contextualize the "Broker Non-Votes" (20,921,414) recorded for all director nominees.
- Review the definitive proxy statement filed on April 25, 2025, for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Confirm the Company's status as an emerging growth company and any implications for future financial reporting standards.